{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T12:22:46Z","timestamp":1763468566853,"version":"3.37.3"},"reference-count":102,"publisher":"Bentham Science Publishers Ltd.","issue":"12","funder":[{"DOI":"10.13039\/501100010550","name":"Generalitat of Catalonia","doi-asserted-by":"publisher","award":["2017SGR-1477"],"award-info":[{"award-number":["2017SGR-1477"]}],"id":[{"id":"10.13039\/501100010550","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["M-ERA-NET\/0004\/2015-PAIRED"],"award-info":[{"award-number":["M-ERA-NET\/0004\/2015-PAIRED"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["M-ERA-NET\/0004\/2015-PAIRED"],"award-info":[{"award-number":["M-ERA-NET\/0004\/2015-PAIRED"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPD"],"published-print":{"date-parts":[[2020,5,6]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Glaucoma constitutes the second cause of blindness worldwide and it is considered a neurodegenerative\ndisorder. In this sense, Alzheimer\u2019s disease, which is the most common type of dementia, also causes neurodegeneration.\nThe association between both diseases remains unknown although it has been hypothesised that a\npossible connection might exist and it will be analysed throughout the review. In this sense, nanoparticulate systems\nand specially, lipid nanoparticles could be the key for effective neuroprotection. Lipid nanoparticles are the\nmost recent type of drug nanoparticulate systems. These nanoparticles have shown great potential to encapsulate\nhydrophobic drugs increasing their bioavailability and being able to deliver them to the target tissue. In addition,\nthey have shown great potential for ocular drug delivery. This review explores the most recent strategies employing\nlipid nanoparticles for AD and glaucoma.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1381612826666200218101231","type":"journal-article","created":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T12:43:36Z","timestamp":1582029816000},"page":"1235-1250","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Lipid Nanoparticles as Carriers for the Treatment of Neurodegeneration Associated with Alzheimer\u2019s Disease and Glaucoma: Present and Future Challenges"],"prefix":"10.2174","volume":"26","author":[{"given":"Elena S.","family":"L\u00f3pez","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy, University of Barcelona, Barcelona 08028, Spain"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0342-1535","authenticated-orcid":true,"given":"Ana L.L.","family":"Machado","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy, University of Barcelona, Barcelona 08028, Spain"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2043-2092","authenticated-orcid":true,"given":"Lorena B.","family":"Vidal","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy, University of Barcelona, Barcelona 08028, Spain"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8019-6792","authenticated-orcid":true,"given":"Roberto","family":"Gonz\u00e1lez-Pizarro","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy, University of Barcelona, Barcelona 08028, Spain"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7524-9914","authenticated-orcid":true,"given":"Amelia D.","family":"Silva","sequence":"additional","affiliation":[{"name":"Department of Biology and Environment, University of Tras-os-Montes e Alto Douro (UTAD), 5001-801 Vila Real, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9737-6017","authenticated-orcid":true,"given":"Eliana B.","family":"Souto","sequence":"additional","affiliation":[{"name":"CEB - Centre of Biological Engineering, University of Minho, Campus de Gualtar 4710-057 Braga, Portugal"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1080\/17425247.2016.1201059","volume":"13","author":"Battaglia L.","year":"2016","unstructured":"Battaglia L.; Serpe L.; Foglietta F.; Muntoni E.; Gallarate M.; Del Pozo Rodriguez A.; Solinis M.A.; Application of lipid nanoparticles to ocular drug delivery. Expert Opin Drug Deliv 2016,13(12),1743-1757","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1136\/bjophthalmol-2013-304028","volume":"98","author":"Kim N.J.","year":"2014","unstructured":"Kim N.J.; Harris A.; Gerber A.; Tobe L.A.; Amireskandari A.; Huck A.; Siesky B.; Nanotechnology and glaucoma: a review of the potential implications of glaucoma nanomedicine. Br J Ophthalmol 2014,98(4),427-431","journal-title":"Br J Ophthalmol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/j.1755-3768.2011.02125.x","volume":"90","author":"Bach-Holm D.","year":"2012","unstructured":"Bach-Holm D.; Kessing S.V.; Mogensen U.; Forman J.L.; Andersen P.K.; Kessing L.V.; Normal tension glaucoma and Alzheimer disease: comorbidity? Acta Ophthalmol 2012,90(7),683-685","journal-title":"Acta Ophthalmol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2174\/157016311796799062","volume":"8","author":"M\u00fcller R.H.","year":"2011","unstructured":"M\u00fcller R.H.; Shegokar R.; Keck C.M.; 20 years of lipid nanoparticles (SLN and NLC): present state of development and industrial applications. Curr Drug Discov Technol 2011,8(3),207-227","journal-title":"Curr Drug Discov Technol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.ophtha.2011.11.003","volume":"119","author":"Chang E.E.","year":"2012","unstructured":"Chang E.E.; Goldberg J.L.; Glaucoma 2.0: neuroprotection, neuroregeneration, neuroenhancement. Ophthalmology 2012,119(5),979-986","journal-title":"Ophthalmology"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.revmed.2018.12.001","volume":"40","author":"Bertaud S.","year":"2019","unstructured":"Bertaud S.; Aragno V.; Baudouin C.; Labb\u00e9 A.; [Primary open-angle glaucoma]. Rev Med Interne 2019,40(7),445-452","journal-title":"Rev Med Interne"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.4103\/0301-4738.73682","volume":"59","author":"Pan Y.","year":"2011","unstructured":"Pan Y.; Rohit V.Natural history of glaucoma. Indian J Ophthalmol 2011,59(Suppl  1.),S19-S23","journal-title":"Indian J Ophthalmol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2014.3192","volume":"311","author":"Weinreb R.N.","year":"2014","unstructured":"Weinreb R.N.; Aung T.; Medeiros F.A.; The pathophysiology and treatment of glaucoma: a review. JAMA 2014,311(18),1901-1911","journal-title":"JAMA"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","volume":"14","author":"Heneka M.T.","year":"2015","unstructured":"Heneka M.T.; Carson M.J.; El Khoury J.; Landreth G.E.; Brosseron F.; Feinstein D.L.; Jacobs A.H.; Wyss-Coray T.; Vitorica J.; Ransohoff R.M.; Herrup K.; Frautschy S.A.; Finsen B.; Brown G.C.; Verkhratsky A.; Yamanaka K.; Koistinaho J.; Latz E.; Halle A.; Petzold G.C.; Town T.; Morgan D.; Shinohara M.L.; Perry V.H.; Holmes C.; Bazan N.G.; Brooks D.J.; Hunot S.; Joseph B.; Deigendesch N.; Garaschuk O.; Boddeke E.; Dinarello C.A.; Breitner J.C.; Cole G.M.; Golenbock D.T.; Kummer M.P.; Neuroinflammation in Alzheimer\u2019s disease. Lancet Neurol 2015,14(4),388-405","journal-title":"Lancet Neurol"},{"key":"ref=10","first-page":"57","volume":"6","author":"Sit A.J.","year":"2009","unstructured":"Sit A.J.; Liu J.H.K.; Pathophysiology of glaucoma and continuous measurements of intraocular pressure. Mol Cell Biomech 2009,6(1),57-69","journal-title":"Mol Cell Biomech"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuroscience.2010.12.036","volume":"176","author":"Crish S.D.","year":"2011","unstructured":"Crish S.D.; Calkins D.J.; Neurodegeneration in glaucoma: progression and calcium-dependent intracellular mechanisms. Neuroscience 2011,176,1-11","journal-title":"Neuroscience"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.preteyeres.2012.07.001","volume":"31","author":"Calkins D.J.","year":"2012","unstructured":"Calkins D.J.; Critical pathogenic events underlying progression of neurodegeneration in\u00a0glaucoma. Prog Retin Eye Res 2012,31(6),702-719","journal-title":"Prog Retin Eye Res"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.preteyeres.2006.07.003","volume":"25","author":"Tezel G.","year":"2006","unstructured":"Tezel G.; Oxidative stress in glaucomatous neurodegeneration: mechanisms and consequences. Prog Retin Eye Res 2006,25(5),490-513","journal-title":"Prog Retin Eye Res"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jalz.2018.02.001","volume":"14","author":"Association A.","year":"2018","unstructured":"Association A.; Alzheimer\u2019s disease facts and figures. Alzheimers Dement 2018,14,367-429","journal-title":"Alzheimers Dement"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.jalz.2016.03.001","volume":"12","author":"Gaugler J.","year":"2016","unstructured":"Gaugler J.; James B.; Johnson T.; Scholz K.; Weuve J.;  Alzheimer\u2019s disease facts and figures. Alzheimers Dement 2016,12(4),459-509","journal-title":"Alzheimers Dement"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"Selkoe D.J.","year":"2016","unstructured":"Selkoe D.J.; Hardy J.; The amyloid hypothesis of Alzheimer\u2019s disease at 25\u00a0years. EMBO Mol Med 2016,8(6),595-608","journal-title":"EMBO Mol Med"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"Jack C.R.","year":"2018","unstructured":"Jack C.R.; Bennett D.A.; Blennow K.; Carrillo M.C.; Dunn B.; Haeberlein S.B.; Holtzman D.M.; Jagust W.; Jessen F.; Karlawish J.; Liu E.; Molinuevo J.L.; Montine T.; Phelps C.; Rankin K.P.; Rowe C.C.; Scheltens P.; Siemers E.; Snyder H.M.; Sperling R.; NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement 2018,14(4),535-562","journal-title":"Alzheimers Dement"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1212\/WNL.0b013e31828726f5","volume":"80","author":"Hebert L.E.","year":"2013","unstructured":"Hebert L.E.; Weuve J.; Scherr P; Alzheimer disease in the United States (2020-2050) estimated using  2010 census. Neurology 2013,80(19),1778-1783","journal-title":"Neurology"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1006\/exnr.1995.1025","volume":"133","author":"Smale G.","year":"1995","unstructured":"Smale G.; Nichols N.R.; Brady D.R.; Finch C.E.; Horton W.E.; Evidence for apoptotic cell death in Alzheimer\u2019s disease. Exp Neurol 1995,133(2),225-230","journal-title":"Exp Neurol"},{"key":"ref=20","first-page":"4","volume":"17","author":"Bastard J.P.","year":"2006","unstructured":"Bastard J.P.; Maachi M.; Lagathu C.; Kim M.J.; Caron M.; Vidal H.; Capeau J.; Feve B.; Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006,17(1),4-12","journal-title":"Eur Cytokine Netw"},{"key":"ref=21","first-page":"450","volume":"14","author":"Cheignon C.","year":"2018","unstructured":"Cheignon C.; Tomas M.; Bonnefont-Rousselot D.; Faller P.; Hureau C.; Collin F.; Oxidative stress and the amyloid beta peptide in Alzheimer\u2019s disease. In:Redox Biol 2018,14,450-464","journal-title":"In:Redox Biol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1136\/bjo.2008.148064","volume":"93","author":"Wostyn P.","year":"2009","unstructured":"Wostyn P.; Audenaert K.; De Deyn P.P.; Alzheimer\u2019s disease and glaucoma: is there a causal relationship? Br J Ophthalmol 2009,93(12),1557-1559","journal-title":"Br J Ophthalmol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1056\/NEJM198608213150804","volume":"315","author":"Hinton D.R.","year":"1986","unstructured":"Hinton D.R.; Sadun A.A.; Blanks J.C.; Miller C.A.; Optic-nerve degeneration in Alzheimer\u2019s disease. N Engl J Med 1986,315(8),485-487","journal-title":"N Engl J Med"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/0197-4580(96)00010-3","volume":"17","author":"Blanks J.C.","year":"1996","unstructured":"Blanks J.C.; Torigoe Y.; Hinton D.R.; Blanks R.H.I.; Retinal pathology in Alzheimer\u2019s disease. I. Ganglion cell loss in foveal\/parafoveal retina. Neurobiol Aging 1996,17(3),377-384","journal-title":"Neurobiol Aging"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s10384-004-0156-x","volume":"49","author":"Yoneda S.","year":"2005","unstructured":"Yoneda S.; Hara H.; Hirata A.; Fukushima M.; Inomata Y.; Tanihara H.; Vitreous fluid levels of \u03b2-amyloid((1-42)) and tau in patients with retinal diseases. Jpn J Ophthalmol 2005,49(2),106-108","journal-title":"Jpn J Ophthalmol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"s1140","DOI":"10.2741\/1172","volume":"8","author":"McKinnon S.J.","year":"2003","unstructured":"McKinnon S.J.; Glaucoma: ocular Alzheimer\u2019s disease? Front Biosci 2003,8,s1140-s1156","journal-title":"Front Biosci"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"7837","DOI":"10.1523\/JNEUROSCI.15-12-07837.1995","volume":"15","author":"LeBlanc A.","year":"1995","unstructured":"LeBlanc A.; Increased production of 4 kDa amyloid \u03b2 peptide in serum deprived human primary neuron cultures: possible involvement of apoptosis. J Neurosci 1995,15(12),7837-7846","journal-title":"J Neurosci"},{"key":"ref=28","first-page":"21","volume":"9","author":"Laferla F.M.","year":"1995","unstructured":"Laferla F.M.; Tinkle B.; Bieberich C.J.; Haudenschild C.C.; The Alzheimer\u2019s Abeta peptide nduces neurodegeneration transgenic mice. Nature 1995,9,21-30","journal-title":"Nature"},{"key":"ref=29","first-page":"1077","volume":"43","author":"McKinnon S.J.","year":"2002","unstructured":"McKinnon S.J.; Lehman D.M.; Kerrigan-Baumrind L.A.; Merges C.A.; Pease M.E.; Kerrigan D.F.; Ransom N.L.; Tahzib N.G.; Reitsamer H.A.; Levkovitch-Verbin H.; Quigley H.A.; Zack D.J.; Caspase activation and amyloid precursor protein cleavage in rat ocular hypertension. Invest Ophthalmol Vis Sci 2002,43(4),1077-1087","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S0092-8674(00)80748-5","volume":"97","author":"Gervais F.G.","year":"1999","unstructured":"Gervais F.G.; Xu D.; Robertson G.S.; Vaillancourt J.P.; Zhu Y.; Huang J.; LeBlanc A.; Smith D.; Rigby M.; Shearman M.S.; Clarke E.E.; Zheng H.; Van Der Ploeg L.H.; Ruffolo S.C.; Thornberry N.A.; Xanthoudakis S.; Zamboni R.J.; Roy S.; Nicholson D.W.; Involvement of caspases in proteolytic cleavage of Alzheimer\u2019s amyloid-beta precursor protein and amyloidogenic A beta peptide formation. Cell 1999,97(3),395-406","journal-title":"Cell"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.ijpharm.2018.05.050","volume":"547","author":"Gonzalez-Pizarro R.","year":"2018","unstructured":"Gonzalez-Pizarro R.; Silva-Abreu M.; Calpena A.C.; Egea M.A.; Espina M.; Garc\u00eda M.L.; Development of fluorometholone-loaded PLGA nanoparticles for treatment of inflammatory disorders of anterior and posterior segments of the eye. Int J Pharm 2018,547(1-2),338-346","journal-title":"Int J Pharm"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.nano.2016.12.003","volume":"13","author":"S\u00e1nchez-L\u00f3pez E.","year":"2017","unstructured":"S\u00e1nchez-L\u00f3pez E.; et al.New potential strategies for Alzheimer\u2019s disease prevention: pegylated biodegradable dexibuprofen nanospheres administration to APPswe\/PS1dE9. Nanomedicine 2017,13(3),1171-1182","journal-title":"Nanomedicine"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.colsurfb.2016.04.054","volume":"145","author":"S\u00e1nchez-L\u00f3pez E.","year":"2016","unstructured":"S\u00e1nchez-L\u00f3pez E.; Egea M.A.; Cano A.; Espina M.; Calpena A.C.; Ettcheto M.; Camins A.; Souto E.B.; Silva A.M.; Garc\u00eda M.L.; PEGylated PLGA nanospheres optimized by design of experiments for ocular administration of dexibuprofen-in vitro, ex vivo and in vivo characterization. Colloids Surf B Biointerfaces 2016,145,241-250","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.scp.2017.07.002","volume":"6","author":"Ganesan P.","year":"2017","unstructured":"Ganesan P.; Narayanasamy D.; Lipid nanoparticles: different preparation techniques, characterization, hurdles, and strategies for the production of solid lipid nanoparticles and nanostructured lipid carriers for oral drug delivery. Sustain Chem Pharm 2017,6(May),37-56","journal-title":"Sustain Chem Pharm"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ejpb.2016.10.009","volume":"110","author":"S\u00e1nchez-L\u00f3pez E.","year":"2017","unstructured":"S\u00e1nchez-L\u00f3pez E.; Espina M.; Doktorovova S.; Souto E.B.; Garc\u00eda M.L.; Lipid nanoparticles (SLN, NLC): Overcoming the anatomical and physiological barriers of the eye - Part I - Barriers and determining factors in ocular delivery. Eur J Pharm Biopharm 2017,110,70-75","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"305","DOI":"10.15171\/apb.2015.043","volume":"5","author":"Naseri N.","year":"2015","unstructured":"Naseri N.; Valizadeh H.; Zakeri-Milani P.; Solid lipid nanoparticles and nanostructured lipid carriers: structure preparation and application. Adv Pharm Bull 2015,5(3),305-313","journal-title":"Adv Pharm Bull"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.tifs.2018.05.018","volume":"78","author":"Shishir M.R.I.","year":"2018","unstructured":"Shishir M.R.I.; Xie L.; Sun C.; Zheng X.; Chen W.; Advances in micro and nano-encapsulation of bioactive compounds using biopolymer and lipid-based transporters. Trends Food Sci Technol 2018,78,34-60","journal-title":"Trends Food Sci Technol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/jps.22784","volume":"101","author":"Gonzalez-Mira E.","year":"2012","unstructured":"Gonzalez-Mira E.; Nikoli\u0107 S.; Calpena A.C.; Egea M.A.; Souto E.B.; Garc\u00eda M.L.; Improved and safe transcorneal delivery of flurbiprofen by NLC and NLC-based hydrogels. J Pharm Sci 2012,101(2),707-725","journal-title":"J Pharm Sci"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"537","DOI":"10.3109\/02713681003760168","volume":"35","author":"Souto E.B.","year":"2010","unstructured":"Souto E.B.; Doktorovova S.; Gonzalez-Mira E.; Egea M.A.; Garcia M.L.; Feasibility of lipid nanoparticles for ocular delivery of anti-inflammatory drugs. Curr Eye Res 2010,35(7),537-552","journal-title":"Curr Eye Res"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ijpharm.2012.04.060","volume":"432","author":"Bhatta R.S.","year":"2012","unstructured":"Bhatta R.S.; Chandasana H.; Chhonker Y.S.; Rathi C.; Kumar D.; Mitra K.; Shukla P.K.; Mucoadhesive nanoparticles for prolonged ocular delivery of natamycin: In vitro and pharmacokinetics studies. Int J Pharm 2012,432(1-2),105-112","journal-title":"Int J Pharm"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.clindermatol.2014.10.006","volume":"33","author":"Kels B.D.","year":"2015","unstructured":"Kels B.D.; Grzybowski A.; Grant-Kels J.M.; Human ocular anatomy. Clin Dermatol 2015,33(2),140-146","journal-title":"Clin Dermatol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.ijbiomac.2018.05.113","volume":"116","author":"Liu D.","year":"2018","unstructured":"Liu D.; Lian Y.; Fang Q.; Liu L.; Zhang J.; Li J.; Hyaluronic-acid-modified lipid-polymer hybrid nanoparticles as an efficient ocular delivery platform for moxifloxacin hydrochloride. Int J Biol Macromol 2018,116,1026-1036","journal-title":"Int J Biol Macromol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3109\/08982104.2014.891231","volume":"24","author":"Wang F.","year":"2014","unstructured":"Wang F.; Chen L.; Jiang S.; He J.; Zhang X.; Peng J.; Xu Q.; Li R.; Optimization of methazolamide-loaded solid lipid nanoparticles for ophthalmic delivery using Box-Behnken design. J Liposome Res 2014,24(3),171-181","journal-title":"J Liposome Res"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1080\/02713683.2018.1536218","volume":"44","author":"Cardigos J.","year":"2019","unstructured":"Cardigos J.; Ferreira Q.; Cris\u00f3stomo S.; Moura-Coelho N.; Cunha J.P.; Pinto L.A.; Ferreira J.T.; Nanotechnology-ocular devices for glaucoma treatment: a literature review. Curr Eye Res 2019,44(2),111-117","journal-title":"Curr Eye Res"},{"key":"ref=45","first-page":"1","author":"Long B.","year":"2018","unstructured":"Long B.;  Anatomy of the eyeHandbook of Emergency Ophthalmology 2018,1-12","journal-title":"Anatomy of the eyeHandbook of Emergency Ophthalmology"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/eye.2016.216","volume":"31","author":"Chirco K.R.","year":"2017","unstructured":"Chirco K.R.; Sohn E.H.; Stone E.M.; Tucker B.A.; Mullins R.F.; Structural and molecular changes in the aging choroid: implications for age-related macular degeneration. Eye (Lond) 2017,31(1),10-25","journal-title":"Eye (Lond)"},{"key":"ref=47","first-page":"13","author":"J. Salazar","year":"2018","unstructured":"J. Salazar; Ana I.; Ram\u00edrez et al. Anatomy of the Human Optic Nerve: Structure and Function INTech Open, vol i, no tourism 2018,13"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1463-5224.2007.00585.x","volume":"10","author":"Mangan B.G.","year":"2007","unstructured":"Mangan B.G.; Al-Yahya K.; Chen C.T.; Gionfriddo J.R.; Powell C.C.; Dubielzig R.R.; Ehrhart E.J.; Madl J.E.; Retinal pigment epithelial damage, breakdown of the blood-retinal barrier, and retinal inflammation in dogs with primary glaucoma. Vet Ophthalmol 2007,10(Suppl. 1),117-124","journal-title":"Vet Ophthalmol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.preteyeres.2008.09.003","volume":"27","author":"Kaur C.","year":"2008","unstructured":"Kaur C.; Foulds W.S.; Ling E.A.; Blood-retinal barrier in hypoxic ischaemic conditions: basic concepts, clinical features and management. Prog Retin Eye Res 2008,27(6),622-647","journal-title":"Prog Retin Eye Res"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.addr.2006.07.024","volume":"58","author":"Mannermaa E.","year":"2006","unstructured":"Mannermaa E.; Vellonen K.S.; Urtti A.; Drug transport in corneal epithelium and blood-retina barrier: emerging role of transporters in ocular pharmacokinetics. Adv Drug Deliv Rev 2006,58(11),1136-1163","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=51","first-page":"305","volume":"23","author":"Shah R.","year":"2015","unstructured":"Shah R.; Eldridge D.; Palombo E.; Harding I.; Lipid nanoparticles: production, characterization and stability. Ther Drug Monit 2015,23(4),305-315","journal-title":"Ther Drug Monit"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0939-6411(00)00087-4","volume":"50","author":"Muller R.H.","year":"2000","unstructured":"Muller R.H.; M\u00e4der K.; Gohla S.; Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 2000,50,161-177","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=53","first-page":"80","volume":"2","author":"Ekambaram P.","year":"2012","unstructured":"Ekambaram P.; Sathali A.H.; Priyanka K.; A review on solid lipid nanoparticles. Sci Revs Chem Commun 2012,2(1),80-102","journal-title":"Sci Revs Chem Commun"},{"key":"ref=54","first-page":"8","volume":"5","author":"Yadav N.","year":"2013","unstructured":"Yadav N.; Khatak S.; Singh Sara U.V.; Solid lipid nanoparticles- A review. Int J Appl Pharm 2013,5(2),8-18","journal-title":"Int J Appl Pharm"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3329\/icpj.v1i11.12065","volume":"1","author":"Garud A.","year":"2012","unstructured":"Garud A.; Singh D.; Garud N.; Solid Lipid Nanoparticles (SLN): method, characterization and applications. Int Curr Pharm J 2012,1(11),384-393","journal-title":"Int Curr Pharm J"},{"key":"ref=56","first-page":"34","volume":"2","author":"Ramteke K.H.S.","year":"2012","unstructured":"Ramteke K.H.S.; Joshi, and S. Dhole, \u201cSolid lipid nanoparticles- A review. IOSR J Pharm 2012,2(6),34-44","journal-title":"IOSR J Pharm"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.nano.2015.09.004","volume":"12","author":"Beloqui A.","year":"2016","unstructured":"Beloqui A.; Solin\u00eds M.\u00c1.; Rodr\u00edguez-Gasc\u00f3n A.; Almeida A.J.; Pr\u00e9at V.; Nanostructured lipid carriers: Promising drug delivery systems for future clinics. Nanomedicine (Lond) 2016,12(1),143-161","journal-title":"Nanomedicine (Lond)"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.colsurfb.2011.09.038","volume":"90","author":"Schafroth N.","year":"2012","unstructured":"Schafroth N.; Arpagaus C.; Jadhav U.Y.; Makne S.; Douroumis D.; Nano and microparticle engineering of water insoluble drugs using a novel spray-drying process. Colloids Surf B Biointerfaces 2012,90(1),8-15","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jconrel.2017.08.033","volume":"264","author":"Tapeinos C.","year":"2017","unstructured":"Tapeinos C.; Battaglini M.; Ciofani G.; Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases. J Control Release 2017,264,306-332","journal-title":"J Control Release"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ejpb.2018.10.017","volume":"133","author":"Gordillo-Galeano A.","year":"2018","unstructured":"Gordillo-Galeano A.; Mora-Huertas C.E.; Solid lipid nanoparticles and nanostructured lipid carriers: A review emphasizing on particle structure and drug release. Eur J Pharm Biopharm 2018,133,285-308","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1080\/02713680903017500","volume":"34","author":"Attama A.A.","year":"2009","unstructured":"Attama A.A.; Reichl S.; M\u00fcller-Goymann C.C.; Sustained release and permeation of timolol from surface-modified solid lipid nanoparticles through bioengineered human cornea. Curr Eye Res 2009,34(8),698-705","journal-title":"Curr Eye Res"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jddst.2017.07.001","volume":"42","author":"Andr\u00e9s-Guerrero V.","year":"2017","unstructured":"Andr\u00e9s-Guerrero V.; Bravo-Osuna I.; Pastoriza P.; Molina-Martinez R.; Herrero-Vanrell I.T.; Novel technologies for the delivery of ocular therapeutics in glaucoma. J Drug Deliv Sci Technol 2017,42,180-186","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.ijpharm.2015.10.043","volume":"496","author":"El-Salamouni N.S.","year":"2015","unstructured":"El-Salamouni N.S.; Farid R.M.; El-Kamel A.H.; El-Gamal S.S.; Effect of sterilization on the physical stability of brimonidine-loaded solid lipid nanoparticles and nanostructured lipid carriers. Int J Pharm 2015,496(2),976-983","journal-title":"Int J Pharm"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3109\/02652048.2010.539304","volume":"28","author":"Li R.","year":"2011","unstructured":"Li R.; Jiang S.; Liu D.; Bi X.; Wang F.; Zhang Q.; Xu Q.; A potential new therapeutic system for glaucoma: solid lipid nanoparticles containing methazolamide. J Microencapsul 2011,28(2),134-141","journal-title":"J Microencapsul"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"849","DOI":"10.3109\/1061186X.2014.939983","volume":"22","author":"Wang F.","year":"2014","unstructured":"Wang F.; Chen L.; Zhang D.; Jiang S.; Shi K.; Huang Y.; Li R.; Xu Q.; Methazolamide-loaded solid lipid nanoparticles modified with low-molecular weight chitosan for the treatment of glaucoma: vitro and vivo study. J Drug Target 2014,22(9),849-858","journal-title":"J Drug Target"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/j.1600-079X.2010.00762.x","volume":"48","author":"Belforte N.A.","year":"2010","unstructured":"Belforte N.A.; Moreno M.C.; de Zaval\u00eda N.; Sande P.H.; Chianelli M.S.; Keller Sarmiento M.I.; Rosenstein R.E.; Melatonin: a novel neuroprotectant for the treatment of glaucoma. J Pineal Res 2010,48(4),353-364","journal-title":"J Pineal Res"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.2174\/1570159X15666170313123454","volume":"15","author":"Shukla M.","year":"2017","unstructured":"Shukla M.; Govitrapong P.; Boontem P.; Reiter R.J.; Satayavivad J.; Mechanisms of melatonin in alleviating Alzheimer\u2019s disease. Curr Neuropharmacol 2017,15(7),1010-1031","journal-title":"Curr Neuropharmacol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/j.2042-7158.2010.01225.x","volume":"63","author":"Dhawan S.","year":"2011","unstructured":"Dhawan S.; Kapil R.; Singh B.; Formulation development and systematic optimization of solid lipid nanoparticles of quercetin for improved brain delivery. J Pharm Pharmacol 2011,63(3),342-351","journal-title":"J Pharm Pharmacol"},{"journal-title":"Development and evaluation of Quercetin nanoparticles and hot melt cast films for neuroprotectionMater Sci","author":"Truong C.T.","key":"ref=69","unstructured":"Truong C.T.;  Development and evaluation of Quercetin nanoparticles and hot melt cast films for neuroprotectionMater Sci 2017; 188."},{"key":"ref=70","first-page":"4710","author":"Loureiro A","year":"2017","unstructured":"Loureiro A; Cavaco-paulo A;  Size controlled protein nanoemulsions for cancer therapyCent Biol Eng 2017,4710","journal-title":"Size controlled protein nanoemulsions for cancer therapyCent Biol Eng"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12951-016-0177-x","volume":"14","author":"Neves A.R.","year":"2016","unstructured":"Neves A.R.; Queiroz J.F.; Reis S.; Brain-targeted delivery of resveratrol using solid lipid nanoparticles functionalized with apolipoprotein E. J Nanobiotechnology 2016,14(1),27","journal-title":"J Nanobiotechnology"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3109\/1061186X.2012.747529","volume":"21","author":"Yusuf M.","year":"2013","unstructured":"Yusuf M.; Khan M.; Khan R.A.; Ahmed B.; Biochemical evaluation of brain targeted piperidine solid lipid nanoparticles in an experimentally induced Alzheimer\u2019s disease model. J Drug Target 2013,21(3),300-311","journal-title":"J Drug Target"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejphar.2014.11.014","volume":"747","author":"Sachdeva A.K.","year":"2015","unstructured":"Sachdeva A.K.; Misra S.; Pal Kaur I.; Chopra K.; Neuroprotective potential of sesamol and its loaded solid lipid nanoparticles in ICV-STZ-induced cognitive deficits: behavioral and biochemical evidence. Eur J Pharmacol 2015,747,132-140","journal-title":"Eur J Pharmacol"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1080\/10715760903214454","volume":"43","author":"Picone P.","year":"2009","unstructured":"Picone P.; Bondi M.L.; Montana G.; Bruno A.; Pitarresi G.; Giammona G.; Di Carlo M.; Ferulic acid inhibits oxidative stress and cell death induced by Ab oligomers: improved delivery by solid lipid nanoparticles. Free Radic Res 2009,43(11),1133-1145","journal-title":"Free Radic Res"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"169","DOI":"10.5640\/insc.0104169","volume":"1","author":"Nazem A.","year":"2011","unstructured":"Nazem A.; Mansoori G.A.; Nanotechnology for Alzheimer\u2019s disease detection and treatment. Insciences J 2011,1(4),169-193","journal-title":"Insciences J"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1016\/j.fct.2011.08.006","volume":"49","author":"Kakkar V.","year":"2011","unstructured":"Kakkar V.; Kaur I.P.; Evaluating potential of curcumin loaded solid lipid nanoparticles in aluminium induced behavioural, biochemical and histopathological alterations in mice brain. Food Chem Toxicol 2011,49(11),2906-2913","journal-title":"Food Chem Toxicol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ejpb.2016.10.013","volume":"110","author":"S\u00e1nchez-L\u00f3pez E.","year":"2017","unstructured":"S\u00e1nchez-L\u00f3pez E.; Espina M.; Doktorovova S.; Souto E.B.B.; Garc\u00eda M.L.L.; Lipid nanoparticles (SLN, NLC): Overcoming the anatomical and physiological barriers of the eye - Part II - Ocular drug-loaded lipid nanoparticles. Eur J Pharm Biopharm 2017,110,58-69","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijpharm.2006.08.030","volume":"330","author":"Gao P.","year":"2007","unstructured":"Gao P.; Xu H.; Ding P.; Gao Q.; Sun J.; Chen D.; Controlled release of huperzine A from biodegradable microspheres: In vitro and in vivo studies. Int J Pharm 2007,330(1-2),1-5","journal-title":"Int J Pharm"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3390\/nu8040200","volume":"8","author":"Abu-Amero K.K.","year":"2016","unstructured":"Abu-Amero K.K.; Kondkar A.A.; Chalam K.V.; Resveratrol and ophthalmic diseases. Nutrients 2016,8(4),200","journal-title":"Nutrients"},{"key":"ref=80","first-page":"134","volume":"12","author":"Anubhav A.","year":"2017","unstructured":"Anubhav A.; Malti A.; Gyanendra S.; Gaurav K.; Shubhini A.S.; Design and development of resveratrol NLCs and their role in synaptic transmission of acetylcholine in C. elegans model. Curr Drug Ther 2017,12(2),134-148","journal-title":"Curr Drug Ther"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ejps.2014.04.019","volume":"60","author":"Serralheiro A.","year":"2014","unstructured":"Serralheiro A.; Alves G.; Fortuna A.; Falc\u00e3o A.; Intranasal administration of carbamazepine to mice: a direct delivery pathway for brain targeting. Eur J Pharm Sci 2014,60,32-39","journal-title":"Eur J Pharm Sci"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.3109\/03639045.2015.1062897","volume":"41","author":"Hanafy A.S.","year":"2015","unstructured":"Hanafy A.S.; Farid R.M.; ElGamal S.S.; Complexation as an approach to entrap cationic drugs into cationic nanoparticles administered intranasally for Alzheimer\u2019s disease management: preparation and detection in rat brain. Drug Dev Ind Pharm 2015,41(12),2055-2068","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jddst.2019.01.040","volume":"51","author":"Rajput A.P.","year":"2019","unstructured":"Rajput A.P.; Butani S.B.; Resveratrol anchored nanostructured lipid carrier loaded in situ gel via nasal route: Formulation, optimization and in vivo characterization. J Drug Deliv Sci Technol 2019,51,214-223","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1007\/s13346-018-0540-6","volume":"8","author":"Rajput A.","year":"2018","unstructured":"Rajput A.; Bariya A.; Allam A.; Othman S.; Butani S.B.; \n                        In situ nanostructured hydrogel of resveratrol for brain targeting: in vitro-in vivo characterization. Drug Deliv Transl Res 2018,8(5),1460-1470","journal-title":"Drug Deliv Transl Res"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"184","DOI":"10.2174\/157488912803252032","volume":"7","author":"Kim D.S.H.L.","year":"2012","unstructured":"Kim D.S.H.L.; Kim J.Y.; Han Y.; Curcuminoids in neurodegenerative diseases. Recent Patents CNS Drug Discov 2012,7(3),184-204","journal-title":"Recent Patents CNS Drug Discov"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"11066","DOI":"10.1038\/s41598-018-29393-8","volume":"8","author":"Davis B.M.","year":"2018","unstructured":"Davis B.M.; Pahlitzsch M.; Guo L.; Balendra S.; Shah P.; Ravindran N.; Malaguarnera G.; Sisa C.; Shamsher E.; Hamze H.; Noor A.; Sornsute A.; Somavarapu S.; Cordeiro M.F.; Topical curcumin nanocarriers are neuroprotective in eye disease. Sci Rep 2018,8(1),11066","journal-title":"Sci Rep"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1021\/acschemneuro.8b00510","volume":"10","author":"Sadegh Malvajerd S.","year":"2019","unstructured":"Sadegh Malvajerd S.; et al.Brain delivery of Curcumin using solid lipid nanoparticles and nanostructured lipid carriers: preparation, optimization, and pharmacokinetic evaluation. ACS Chem Neurosci 2019,10(1),728-739","journal-title":"ACS Chem Neurosci"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.colsurfb.2015.06.025","volume":"134","author":"Meng F.","year":"2015","unstructured":"Meng F.; Asghar S.; Gao S.; Su Z.; Song J.; Huo M.; Meng W.; Ping Q.; Xiao Y.; A novel LDL-mimic nanocarrier for the targeted delivery of curcumin into the brain to treat Alzheimer\u2019s disease. Colloids Surf B Biointerfaces 2015,134,88-97","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ijpharm.2010.05.005","volume":"394","author":"Zhuang C.Y.","year":"2010","unstructured":"Zhuang C.Y.; Li N.; Wang M.; Zhang X.N.; Pan W.S.; Peng J.J.; Pan Y.S.; Tang X.; Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. Int J Pharm 2010,394(1-2),179-185","journal-title":"Int J Pharm"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.brainres.2010.07.098","volume":"1355","author":"Park S.J.","year":"2010","unstructured":"Park S.J.; Kim D.H.; Kim J.M.; Shin C.Y.; Cheong J.H.; Ko K.H.; Ryu J.H.; Mismatch between changes in baicalein-induced memory-related biochemical parameters and behavioral consequences in mouse. Brain Res 2010,1355,141-150","journal-title":"Brain Res"},{"key":"ref=91","volume":"54","author":"Do C","year":"2013","unstructured":"Do C; Leung C; Chan H L H; Civan M; To C;  Baicalein lowers intraocular pressure in gerbils Investig opthalmology Vis Sci 2013,54(13)","journal-title":"Baicalein lowers intraocular pressure in gerbils Investig opthalmology Vis Sci"},{"key":"ref=92","first-page":"2891","volume":"55","author":"Do C","year":"2014","unstructured":"Do C; Leung C; Chan H L H; Civan M; To C;  Ocular hypotensice effect of baicalein in Sprague-Dawley rats Investig opthalmology Vis Sci 2014,55(13),2891","journal-title":"Ocular hypotensice effect of baicalein in Sprague-Dawley rats Investig opthalmology Vis Sci"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.ijpharm.2011.12.009","volume":"423","author":"Tsai M.J.","year":"2012","unstructured":"Tsai M.J.; Wu P.C.; Huang Y.B.; Chang J.S.; Lin C.L.; Tsai Y.H.; Fang J.Y.; Baicalein loaded in tocol nanostructured lipid carriers (tocol NLCs) for enhanced stability and brain targeting. Int J Pharm 2012,423(2),461-470","journal-title":"Int J Pharm"},{"key":"ref=94","first-page":"323","author":"Cacabelos R.","year":"2014","unstructured":"Cacabelos R.; Cacabelos P.; Torrellas C.; Tellado I.; Carril J.C.;  Pharmacogenomics of Alzheimer\u2019s disease: Novel therapeutic strategies for drug development Pharmacogenomics in Drug Discovery and Development Humana Press, New York, NY,2014,323-556","journal-title":"Pharmacogenomics of Alzheimer\u2019s disease: Novel therapeutic strategies for drug development Pharmacogenomics in Drug Discovery and Development"},{"key":"ref=95","author":"Blanco A. R.","year":"2015","unstructured":"Blanco A. R.; Bondi M.L.; Cavallaro G.;  Nanostructured formulations for delivering silibinin and other active ingredients for the treatment of eye diseases WO2016055976A1.2015","journal-title":"Nanostructured formulations for delivering silibinin and other active ingredients for the treatment of eye diseases"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"671","DOI":"10.3109\/10611860903079454","volume":"17","author":"Azeem A.","year":"2009","unstructured":"Azeem A.; Anwer M.K.; Talegaonkar S.; Niosomes in sustained and targeted drug delivery: some recent advances. J Drug Target 2009,17(9),671-689","journal-title":"J Drug Target"},{"key":"ref=97","first-page":"113","volume":"15","author":"Kaur H.","year":"2012","unstructured":"Kaur H.; Dhiman S.; Arora S.; Niosomes: A novel drug delivery system. Int J Pharm Sci Rev Res 2012,15(1),113-120","journal-title":"Int J Pharm Sci Rev Res"},{"key":"ref=98","doi-asserted-by":"crossref","first-page":"7","DOI":"10.22159\/ijap.2019v11i1.29077","volume":"11","author":"Saraswathi T.S.","year":"2019","unstructured":"Saraswathi T.S.; Mothilal M.; Jaganathan M.K.; Niosomes as an emerging formulation tool for drug delivery-a review. Int J Appl Pharm 2019,11(2),7-15","journal-title":"Int J Appl Pharm"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ijpharm.2004.10.026","volume":"290","author":"Aggarwal D.","year":"2005","unstructured":"Aggarwal D.; Kaur I.P.; Improved pharmacodynamics of timolol maleate from a mucoadhesive niosomal ophthalmic drug delivery system. Int J Pharm 2005,290(1-2),155-159","journal-title":"Int J Pharm"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ijpharm.2004.07.020","volume":"285","author":"Dufes C.","year":"2004","unstructured":"Dufes C.; Gaillard F.; Uchegbu I.F.; Sch\u00e4tzlein A.G.; Olivier J.C.; Muller J.M.; Glucose-targeted niosomes deliver vasoactive intestinal peptide (VIP) to the brain. Int J Pharm 2004,285(1-2),77-85","journal-title":"Int J Pharm"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3109\/17435390.2010.489207","volume":"5","author":"Asharani P.V.","year":"2011","unstructured":"Asharani P.V.; Lianwu Y.; Gong Z.; Valiyaveettil S.; Comparison of the toxicity of silver, gold and platinum nanoparticles in developing zebrafish embryos. Nanotoxicology 2011,5(1),43-54","journal-title":"Nanotoxicology"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/molecules22020277","volume":"22","author":"Loureiro J.A.","year":"2017","unstructured":"Loureiro J.A.; Andrade S.; Duarte A.; Neves A.R.; Queiroz J.F.; Nunes C.; Sevin E.; Fenart L.; Gosselet F.; Coelho M.A.; Pereira M.C.; Resveratrol and grape extract-loaded solid lipid nanoparticles for the treatment of Alzheimer\u2019s disease. Molecules 2017,22(2),1-16","journal-title":"Molecules"}],"container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/179474","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T18:40:37Z","timestamp":1592246437000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/179474\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,6]]},"references-count":102,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,5,6]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1381612826666200218101231","relation":{},"ISSN":["1381-6128"],"issn-type":[{"type":"print","value":"1381-6128"}],"subject":[],"published":{"date-parts":[[2020,5,6]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-09-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}